Reproductive Health Planning for Patients with Multiple Sclerosis: A Clinician’s Guide

Wednesday, December 4, 2019
7:30 pm EDT

Program Chair
Patricia K. Coyle, MD
Professor of Neurology
Director, MS Comprehensive Care Center
Stony Brook Neurosciences Institute
Stony Brook, NY

Faculty Participants
Patricia Melville, NP
Nurse Practitioner
Stony Brook Neurosciences Institute
Stony Brook, NY

Statement of Need
Multiple sclerosis (MS) has a female predominance of approximately 3 to 1 and appears to be increasing among young women who are of reproductive age at the time of diagnosis. The impact of the disease and its treatment on the health of a pregnant mother and the developing fetus is a critical issue. While it may seem prudent to recommend that women discontinue disease-modifying therapy (DMT) before pregnancy or if a pregnancy is confirmed, this decision must be made on a case-by-case basis. Healthcare professionals require the latest information about DMT use during pregnancy, including available data on approved therapies and labeling recommendations that may influence this decision-making process.

Target Audience
This activity has been designed to meet the educational needs of healthcare providers who manage patients with multiple sclerosis (MS), including neurologists, obstetricians, primary care physicians, nurses, nurse practitioners, physicians assistants, and pharmacists.

Free Continuing Education (CE) Credit for Physicians, Nurses, NPs, PAs, and Pharmacists.

This activity is supported through an educational grant from Bayer.

This activity is jointly provided by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group.